Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AKR1B1 | P15121 | 3/20 | 0.78 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.65 |
| ▸ | MAOB | P27338 | 2/20 | 0.64 |
| ▸ | POLB | P06746 | 5/20 | 0.59 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.59 |
| ▸ | THRB | P10828 | 2/20 | 0.58 |
| ▸ | TP53 | P04637 | 2/20 | 0.58 |
| ▸ | MAPT | P10636 | 3/20 | 0.54 |
| ▸ | GAA | P10253 | 1/20 | 0.54 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.54 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.53 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.51 |
| ▸ | MEN1 | O00255 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8827849 | 0.89 | AKR1B1 (0.78) | AKR1B1SLC2A1MAOBPOLBKMT2A | |
| SCHEMBL22617461 | 0.89 | MAOB (0.76) | AKR1B1SLC2A1MAOBPOLBKMT2A | |
| SCHEMBL29495537 | 0.87 | AKR1B1 (1.00) | AKR1B1SLC2A1MAOBKMT2AMAPT | |
| SCHEMBL1021783 | 0.87 | AKR1B1 (1.00) | AKR1B1SLC2A1MAOBKMT2AMAPT | |
| SCHEMBL4250015 | 0.87 | AKR1B1 (0.76) | AKR1B1SLC2A1MAOBPOLBKMT2A | |
| SCHEMBL6332284 | 0.86 | AKR1B1 (0.74) | AKR1B1SLC2A1MAOBKMT2ATHRB | |
| SCHEMBL6339410 | 0.86 | MAOB (0.81) | AKR1B1SLC2A1MAOBKMT2ATHRB | |
| SCHEMBL8123206 | 0.85 | AKR1B1 (0.72) | AKR1B1SLC2A1MAOBPOLBKMT2A | |
| SCHEMBL5322779 | 0.85 | KDM4E (0.76) | AKR1B1SLC2A1MAOBKMT2ATP53 | |
| SCHEMBL432503 | 0.85 | SLC2A1 (0.78) | AKR1B1SLC2A1MAOBPOLBMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240018133-A1 | MODULATORS OF THE INTEGRATED STRESS PATHWAY | ABBVIE INC. | 2024-01-18 | — | — | US | disclosed |
| CN-114401952-A | Substituted cycloalkyl compounds as modulators of integrated stress pathways | 卡里科生命科学有限责任公司 | 2022-04-26 | — | — | CN | disclosed |
| EP-3962899-A1 | SUBSTITUTED CYCLOLAKYLS AS MODULATORS OF THE INTEGRATED STRESS PATHWAY | Calico Life Sciences LLC (US) | 2022-03-09 | — | — | EP | disclosed |
| US-20210363136-A1 | MODULATORS OF THE INTEGRATED STRESS PATHWAY | ABBVIE INC. | 2021-11-25 | — | — | US | disclosed |
| WO-2020223536-A1 | SUBSTITUTED CYCLOLAKYLS AS MODULATORS OF THE INTEGRATED STRESS PATHWAY | CALICO LIFE SCIENCES LLC (US) | 2020-11-05 | — | — | WO | disclosed |
| US-8524766-B2 | Modulators of dopamine neurotransmission | NSAB, FILIAL AF NEUROSEARCH SWEDEN AB, SVERIGE (DK) | 2013-09-03 | — | — | US | disclosed |
| US-20110105461-A1 | MODULATORS OF DOPAMINE NEUROTRANSMISSION | NSAB, FILIAL AF NEUROSEARCH SWEDEN AB, SVERIGE (DK) | 2011-05-05 | — | — | US | disclosed |
| EP-0634409-B1 | Process of producing 2-cyano-4-oxo-4H-benzopyran compounds | SUMITOMO CHEMICAL CO (JP) | 2000-04-26 | — | — | EP | disclosed |
| US-5659051-A | Process of producing 2-cyano-4-oxo-4H-benzopyran compounds | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 1997-08-19 | — | — | US | disclosed |
| EP-0634409-A1 | Process of producing 2-cyano-4-oxo-4H-benzopyran compounds | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 1995-01-18 | — | — | EP | disclosed |
| US-5082849-A | Antiinflammatory agents or antiallergens | AVENTIS PHARMACEUTICALS INC. | 1992-01-21 | — | — | US | disclosed |
| EP-0434827-A4 | QUINOLINYL-BENZOPYRAN DERIVATIVES AS ANTAGONISTS OF LEUKOTRIENE D 4? | — | 1992-01-08 | — | — | EP | disclosed |
| EP-0434827-A1 | QUINOLINYL-BENZOPYRAN DERIVATIVES AS ANTAGONISTS OF LEUKOTRIENE D 4? | RORER INTERNATIONAL (HOLDINGS), INC. (US) | 1991-07-03 | — | — | EP | disclosed |
| WO-1991001123-A2 | QUINOLINYL-BENZOPYRAN DERIVATIVES AS ANTAGONISTS OF LEUKOTRIENE D¿4? | RORER INTERNATIONAL (OVERSEAS) INC. (US) | 1991-02-07 | — | — | WO | disclosed |
| US-4977162-A | Quinolinyl-chromone derivatives and use for treatment of hypersensitive ailments | RORER PHARMACEUTICAL CORPORATION (US) | 1990-12-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210363136-A1 | MODULATORS OF THE INTEGRATED STRESS PATHWAY | ATF4, ATF1, DDIT3 | AKR1B1 1312/4885SLC2A1 822/4885MAOB 3069/4885 |
| US-20240018133-A1 | MODULATORS OF THE INTEGRATED STRESS PATHWAY | ATF4, ATF1, DDIT3 | AKR1B1 1312/4885SLC2A1 822/4885MAOB 3069/4885 |
| US-20110105461-A1 | MODULATORS OF DOPAMINE NEUROTRANSMISSION | DBH, SLC18A2, SLC6A3 | AKR1B1 1812/4885SLC2A1 4305/4885MAOB 95/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.